Pfizer turns up defense of smoking cessation drug
NEW YORK (Reuters) - Pfizer Inc on Thursday turned up public relations efforts to defend its drug to help smokers quit after a recent report said there have been hundreds of problems with patients taking Chantix since its 2006 approval.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=j0AVgf" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=j0AVgf)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=GHjkeI" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=GHjkeI) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=YgWTdi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=YgWTdi) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=knKaxi" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=knKaxi)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/305538451" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/305538451/idUSN0527676220080605